Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
Docetaxel probably leads to higher tumour response compared with non‐docetaxel‐containing regimens (moderate certainty).
Combination leads to higher tumour response compared with single‐agent chemotherapy (high certainty).
It is very uncertain whether capecitabine changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
Oxaliplatin probably leads to higher tumour response compared with the same regimen including cisplatin (moderate certainty).
Taxane‐platinum‐fluoropyrimidine combinations may leads to higher tumour response compared with taxane‐platinum (without fluoropyrimidine) (low certainty).
It is very uncertain whether S‐1 changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
5‐FU/cisplatin/anthracycline combinations may leads to higher tumour response compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
Chemotherapy showed no clear difference in tumour response rate compared with biological therapy (low certainty).
It is very uncertain whether chemmotherapy combined with biological therapy changes tumour response rate compared with chemotherapy (very low certainty).
Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
Biological therapy may leads to higher tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
Chemotherapy showed no clear difference in tumour response rate (non‐taxane monotherapy vs taxane monotherapy) compared with chemotherapy (low certainty).
It is very uncertain whether chemotherapy changes tumour response rate (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (very low certainty).